Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.
about
Loss of Niemann Pick type C proteins 1 and 2 greatly enhances HIV infectivity and is associated with accumulation of HIV Gag and cholesterol in late endosomes/lysosomesDeficiency of niemann-pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartmentsVirus entry, assembly, budding, and membrane raftsSpecific association of glycoprotein B with lipid rafts during herpes simplex virus entryEarly steps of retrovirus replicative cycleTamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza virusesRole of Endocytosis and Low pH in Murine Hepatitis Virus Strain A59 Cell EntryCholesterol Effectively Blocks Entry of FlavivirusLipids and membrane microdomains in HIV-1 replicationRoles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactionsFunctional organization of the HIV lipid envelopeCholesterol promotes hemifusion and pore widening in membrane fusion induced by influenza hemagglutinin.Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication.Novel approaches to inhibiting HIV-1 replication.PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infectionCharacterization of the water defect at the HIV-1 gp41 membrane spanning domain in bilayers with and without cholesterol using molecular simulations.New clues to understanding HIV nonprogressors: low cholesterol blocks HIV trans infection.Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals.Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells.An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction.Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review).HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1The Role of Lipids in Retrovirus Replication.Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Envelope lipid-packing as a critical factor for the biological activity and stability of alphavirus particles isolated from mammalian and mosquito cells.Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cellsAll-atom models of the membrane-spanning domain of HIV-1 gp41 from metadynamics.Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization.Dynamics of lipids, cholesterol, and transmembrane α-helices from microsecond molecular dynamics simulations.The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infectionCaveolin-1 associated adenovirus entry into human corneal cells.Fusion-competent state induced by a C-terminal HIV-1 fusion peptide in cholesterol-rich membranes.Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions.The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses
P2860
Q21245090-AE261929-AF45-40D6-B00E-536452903C5CQ24644759-A468D16A-834D-4048-9F75-2849AC6A8838Q24673161-EE81B4B1-549B-4EF8-98A2-77D6D473C7B1Q24683262-6049B45A-C47C-4D2A-B029-6BAD091AD9EBQ24792862-8F37102B-C9E4-4629-BBD8-446EDC91ED4FQ27311553-DE4D0CDD-B963-46DD-9992-812394CFF749Q27481481-72EFA9D9-0F97-47BB-90DD-EA6BF6F3ADE8Q27486412-28E528D7-7E60-4262-949E-8F6B38B976A0Q27489393-C9CD4764-CB9C-4E3E-9A04-618C56105121Q28286819-A4DEC846-FB22-45EC-AC89-246C786292D6Q28828700-1F7FECE5-4D41-42F7-ADEC-3D811DCA44AFQ30440963-3C14E353-B5C3-4DAD-BDD3-A4884FF35CA1Q33262244-377A2060-EC33-40E4-B9F4-2AAD26CBAE9EQ33558319-87863233-D758-4550-9AA4-A318D4C91523Q33624690-0B2AF804-7629-455F-A4E1-C1EADB137248Q33628817-A236024D-2E18-49E8-8971-F50FEFF8B97EQ33694260-4E9C1661-FBB8-40BC-AC04-53B34DBF0516Q33751856-57C5B0E7-22C7-47E0-A10A-21C7A5DDC49BQ33843329-F127F5FD-EEEF-43C8-B31C-74032D6E8BB0Q33908866-85A5D554-96D4-4BA9-B423-813FCCA0806DQ33908887-2E6D0D1A-DA8F-4E4D-AF5E-CBEEB2DD6479Q33967491-934278E4-0ABC-4D4A-BD60-5CC34BAD41B0Q34001144-6E1543C3-A0D0-4B82-B70D-77E046F3B7F9Q34051644-C6BE5B2D-9D67-484C-9993-AD0474B73A92Q34080779-579B97D0-0DA0-4895-AA60-C79150515432Q34146122-DD7888B9-D431-4546-8403-3ABDEA64B143Q34149707-65531D54-9E55-4E80-BB82-E1CFC4228AC1Q34182524-D6054E25-3763-434E-BAC3-6777EAB71406Q34306895-945B6197-B24C-4926-BB1D-D8368E024EADQ34594591-AC6E8148-E70F-47B0-ADB3-3C8E0092CAF3Q34622355-17CE718E-FDFB-4100-802B-26F492094350Q34695601-E372345A-F238-445F-BD19-41C85F55E78CQ35023146-46533298-B250-469E-8FEF-89EFBECCBB50Q35091283-8C8FAA7B-E1B3-4197-B54B-19790D508271Q35168397-5FED167A-4081-4BC9-B5FA-6B0727351C89Q35585420-4C7EBD79-316A-4054-9048-3272BBD739E3Q35850220-599ECD1F-5CDA-41D0-93C2-F3F7854003D2Q35877701-98E1A18D-FE21-457C-890F-78F56F61393CQ35917148-4412BCA0-6468-4489-B985-53981BE15ED4Q36118373-739431B0-E5AC-47C2-9083-301BBAE8F31E
P2860
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role for human immunodeficienc ...... erol in viral internalization.
@ast
Role for human immunodeficienc ...... erol in viral internalization.
@en
Role for human immunodeficienc ...... erol in viral internalization.
@nl
type
label
Role for human immunodeficienc ...... erol in viral internalization.
@ast
Role for human immunodeficienc ...... erol in viral internalization.
@en
Role for human immunodeficienc ...... erol in viral internalization.
@nl
prefLabel
Role for human immunodeficienc ...... erol in viral internalization.
@ast
Role for human immunodeficienc ...... erol in viral internalization.
@en
Role for human immunodeficienc ...... erol in viral internalization.
@nl
P2093
P2860
P1433
P1476
Role for human immunodeficienc ...... erol in viral internalization.
@en
P2093
Didier Trono
Etsuko Kiyokawa
Laurence Abrami
Mireille Guyader
Priscilla Turelli
P2860
P304
10356-10364
P356
10.1128/JVI.76.20.10356-10364.2002
P407
P577
2002-10-01T00:00:00Z